


Anthony J. Viola  
Andre K. Cizmarik  
Jennifer L. Dereka  
Zachary W. Silverman  
EDWARDS WILDMAN PALMER LLP  
Attorneys for Plaintiffs  
Kowa Company, Ltd.,  
Kowa Pharmaceuticals America, Inc., and  
Nissan Chemical Industries, Ltd.  
750 Lexington Ave.  
New York, NY 10022  
(212) 308-4411

14 CV 2758



UNITED STATES DISTRICT COURT  
SOUTHERN DISTRICT OF NEW YORK

Kowa Company, Ltd.,  
Kowa Pharmaceuticals America, Inc., and  
Nissan Chemical Industries, Ltd.,

Plaintiffs,

v.

Amneal Pharmaceuticals, LLC,

Defendant.

Civil Action No. \_\_\_\_\_

**COMPLAINT**

Plaintiffs, Kowa Company, Ltd. ("KCL"), Kowa Pharmaceuticals America, Inc. ("KPA") (collectively, "Kowa"), and Nissan Chemical Industries, Ltd. ("NCI") by their undersigned counsel, for their Complaint against defendant Amneal Pharmaceuticals, LLC ("Amneal"), allege as follows:

### **Jurisdiction and Venue**

1. This is an action for patent infringement arising under the patent laws of the United States, Title 35, United States Code and arising under 35 U.S.C. §§ 271(e)(2), 271(b), 271(c), and 281-283. Subject matter jurisdiction is proper under 28 U.S.C. §§ 1331 and 1338(a). Venue is proper under 28 U.S.C. §§ 1391(b)-(c) and 1400(b). Personal jurisdiction over the defendants in New York is proper under N.Y. C.P.L.R. §§ 301 and 302(a) and because defendants are doing business in this jurisdiction.

### **Parties**

2. KCL is a Japanese corporation having its corporate headquarters and principal place of business in Aichi, Japan. KPA is a wholly owned U.S. subsidiary of KCL. KPA has its corporate headquarters and principal place of business in Montgomery, Alabama and is organized under the laws of Delaware.

3. NCI is a Japanese corporation having its corporate headquarters and principal place of business in Tokyo, Japan.

4. KCL and NCI are engaged in the business of research, developing, manufacturing, and marketing of a broad spectrum of innovative pharmaceutical products, including Livalo<sup>®</sup>.

5. Upon information and belief, Amneal is incorporated in Delaware having a place of business in Bridgewater, New Jersey. Upon information and belief, Amneal filed Abbreviated New Drug Application (“ANDA”) No. 20-5961.

6. Upon information and belief, Amneal is currently transacting business in the Southern District of New York, at least by making and shipping into this Judicial District, or by using, offering to sell or selling or by causing others to use, offer to sell or sell, pharmaceutical products into this Judicial District.

7. Upon information and belief, Amneal derives substantial revenue from interstate and/or international commerce, including substantial revenue from goods used or consumed or services rendered in the State of New York and the Southern District of New York. Amneal is registered with the N.Y. State Department of State, Division of Corporations, to do business as a foreign corporation in New York. By filing its ANDA, Amneal has committed, and unless enjoined, will continue to commit a tortious act without the state of New York, that Amneal expects or should reasonably expect to have consequences in the State of New York including in this Judicial District.

#### **The New Drug Application**

8. KPA sells drug products containing pitavastatin calcium (the “pitavastatin drug product”) under the trade name Livalo<sup>®</sup> in the United States pursuant to the United States Food and Drug Administration’s approval of a New Drug Application (“NDA”) held by KCL (NDA No. 22-363).

9. Livalo<sup>®</sup> is approved for use as an adjunctive therapy to diet to reduce elevated total cholesterol, low-density lipoprotein cholesterol, apolipoprotein B, triglycerides, and to increase HDL-C in adult patients with primary hyperlipidemia or mixed dyslipidemia.

10. The approval letter for Livalo<sup>®</sup>, with approved labeling, was issued by the FDA on August 3, 2009.

11. Certain amendments to the approved labeling for Livalo<sup>®</sup> have subsequently been approved.

#### **The Patents in Suit**

12. United States Patent No. 5,856,336 (“the ‘336 patent”), entitled “Quinoline Type Mevalonolactones,” a true and correct copy of which is appended hereto as **Exhibit A**, was duly

issued on January 5, 1999 to inventors Yoshihiro Fujikawa, Mikio Suzuki, Hiroshi Iwasaki, Mitsuaki Sakashita, and Masaki Kitahara, and assigned to plaintiff NCI. The ‘336 patent claims, inter alia, the pitavastatin drug product, and a method for reducing hyperlipidemia, hyperlipoproteinemia or atherosclerosis, which comprises administering an effective amount of the pitavastatin drug product.

13. Plaintiff NCI has been and still is the owner through assignment of the ‘336 patent, which expires on December 25, 2020 pursuant to a patent-term extension. KCL is NCI’s licensee for the ‘336 patent and KPA holds a license from KCL for the ‘336 patent.

14. United States Patent No. 8,557,993 (“the ‘993 patent”), entitled “Crystalline Forms of Pitavastatin Calcium,” a true and correct copy of which is appended hereto as **Exhibit B**, was duly issued on October 15, 2013 to inventors Paul Adriaan Van Der Schaaf, Fritz Blatter, Martin Szelagiewicz, and Kai-Uwe Schoening, and ultimately was assigned to plaintiff NCI. The ‘993 patent claims, inter alia, crystalline polymorphs or the amorphous form of pitavastatin or processes for preparing the same.

15. Plaintiff NCI has been and still is the owner through assignment of the ‘993 patent, which expires on February 2, 2024. KCL is NCI’s licensee for the ‘993 patent and KPA holds a license from KCL for the ‘993 patent.

16. In accordance with its license, KPA sells the pitavastatin drug product under the trade name Livalo<sup>®</sup> in the United States. Sales of Livalo<sup>®</sup> are made pursuant to approval by the FDA of NDA No. 22-363.

17. Plaintiff KCL manufactures the Livalo<sup>®</sup> drug products as sold by KPA.

18. Plaintiffs Kowa and NCI will be substantially and irreparably harmed by infringement of either of the '336 or '993 patents (the "Livalo<sup>®</sup> patents"). There is no adequate remedy at law.

### COUNT I

#### INFRINGEMENT OF THE '336 PATENT UNDER 35 U.S.C. § 271(e)(2)(A)

19. Plaintiffs repeat and incorporate herein by reference the allegations contained in each of the foregoing paragraphs.

20. Upon information and belief, defendant Amneal filed an Abbreviated New Drug Application ("ANDA") with the Food and Drug Administration ("FDA") under 21 U.S.C. § 355(j) (ANDA No. 20-5961) seeking approval to market 1 mg, 2 mg, and 4 mg tablets comprising pitavastatin calcium.

21. By this ANDA filing, Amneal has indicated that it intends to engage, and that there is substantial likelihood that it will engage, in the commercial manufacture, importation, use, offer for sale, and/or sale, or inducement thereof, of Plaintiffs' patented pitavastatin drug product immediately or imminently upon receiving FDA approval to do so. Also by its ANDA filing, Amneal has indicated that its drug product is bioequivalent to Plaintiffs' pitavastatin drug product.

22. By its ANDA filing, Amneal seeks to obtain approval to commercially manufacture, use, import, offer for sale, and/or sell, alleged generic equivalents of Plaintiffs' Livalo<sup>®</sup> pitavastatin drug product prior to the expiration date of the '336 patent.

23. By a letter dated March 5, 2014 (the "Notice Letter"), Amneal informed KCL and NCI that Amneal had filed a certification to the FDA, pursuant to 21 U.S.C. § 355(j)(2)(B)(iv)(I).

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.